KRAS and colorectal carcinoma: In MSLN high-expressing tumors that are MSS, we have reported significantly increased mutation rates in KRAS and FBXW7 as opposed to our findings in MSLN low-expressing patient cohorts, suggesting that MSLN status may also be relevant to the modulation of the TME and immune response in CRC.